ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis

Mo, Zexun; Ye, Meifeng; He, Hua; Huang, Xiaomei; Guo, Weihong; Zhao, Ziwen*; Li, Yujun*; Wei, Shuquan*1
Clinical Medicine Insights: Oncology2023DOI: 10.1177/11795549231215968
9阅读
引用收藏
分享

摘要

Background:Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered as the first-line treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to analyze the efficacy of EGFR-TKIs treatment in patients with advanced NSCLC of different smoking habits.Methods:We conducted a search for meta-analyses and systematic reviews on the PubMed, MEDLINE, Embase, and the Cochrane Library to address this knowledge gap. Patients were divided into 2 groups: (1) experimental group: treated with EGFR-TKIs or EGFR-TKIs combined with chemotherapy, immunotherapy, antiangiogenesis, radiotherapy and (2) control group: treated with chemotherapy. Progressive-free survival (PFS) and total survival (OS) were adopted for evaluating the efficacy of EGFR-TKIs between experimental group and control group.Results:Eleven studies including 6760 patients were included in the meta-analysis. The results showed that smoking (including previous and current smoking) significantly reduces the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs. In addition, EGFR-TKIs combined with anti-vascular endothelial growth factor therapy can reduce the risk of disease progression in smokers.Conclusions:Our study indicated that smoking significantly reduced the PFS and OS in comparison to non-smoking group in the treatment of NSCLC with EGFR-TKIs.

学科与关键词

关键词
Non-small cell lung cancerepidermal growth factor receptor-tyrosine kinase inhibitorsPFSOSsmoking
相关
加载中…
  • The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
    Xinyi, Li; Cong, Huang; Xiaohui, Xie; Ziyang, Wu; Xia, Tian; Yibo, Wu; Xin, Du; Luwen, ShiJournal of Clinical Pharmacy and Therapeutics, 2021, 46(2): 256-266.
  • EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析
    张蓉; 陈薇雅; 甘洁民; 赵虎; 顾兆祥检验医学, 2013, (06): 506.
  • Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
    Li, Dailong; Yao, Ling; Xu, Lu; Li, Wanqiang; Che, Yuan*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2022, 101(48).
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Medicine Insights: Oncology
发表日期
2023
卷期
第 17 卷
页码
11795549231215968
DOI
10.1177/11795549231215968
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong, China [2021A1515012123]; Guangzhou Health Science and Technology Project [20211A011007]

作者

  • M

    Mo, Zexun (第一作者)

    1

  • Y

    Ye, Meifeng

    1

查看全部 8 位作者收起作者
  • H

    He, Hua

    1

  • H

    Huang, Xiaomei

    1

  • G

    Guo, Weihong

    1

  • Z

    Zhao, Ziwen (通讯)

    1

  • L

    Li, Yujun (通讯)

    1

  • W

    Wei, Shuquan (通讯)

    1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417